ArticleBritish journal of haematology2026
Risk factors for silent cerebral infarction in immune-mediated thrombotic thrombocytopenic survivors.
Article in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The quiet brain injury in thrombotic thrombocytopenic purpura: Are we missing the warning signs?British journal of haematology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Immune-mediated thrombotic thrombocytopenic purpura (iTTP) survivors are predisposed to silent cerebral infarctions (SCI) defined as radiological evidence of brain ischaemia without focal symptoms. This study examined risk factors associated with SCI burden in iTTP survivors during remission. We included the first 39 iTTP survivors enrolled in the prospective neurological sequelae of TTP (NeST) study. Participants underwent brain magnetic resonance imaging during clinical remission. SCI burden was quantified using the modified age-related white matter changes (ARWMC) score. Multivariate linear regression models identified the predictors of SCI burden. Of 39 participants, 20 (51.3%) had SCI. On univariate analysis, higher SCI burden was associated with older age, elevated level of peak serum creatinine and peak lactate dehydrogenase (LDH) during the index iTTP episode, comorbidities including diabetes mellitus, prior stroke, coronary artery disease (CAD) and family history of cerebrovascular disease. In the multivariate model, higher SCI burden was significantly associated with older age (p < 0.001), diabetes mellitus (p = 0.007), prior stroke (p = 0.01), CAD (p = 0.02) and elevated peak LDH (p = 0.046). Total days of thrombocytopenia (surrogate for 'days with active iTTP') were not associated with SCI burden. Both modifiable and non-modifiable factors contribute to SCI in iTTP survivors. Targeted management of cardiovascular comorbidities during remission may reduce long-term neurological sequelae. Validation in larger cohorts is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.